Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Emerging specialists in coagulation have until November 7 to apply for support for innovative research.
Like many organizations, the global biotech company is exploring ways to make the shift away from fossil fuels.
A global network of hemophilia treatment centers offers comprehensive care and access to the latest treatments.
CSL Behring employees formed teams that pitched in at three locations across the county of Sussex.
Meet CSL Seqirus’ U.S. Brand Marketing Director – global marketer, dedicated aunt and expert baker.
Monthly cycles can sink iron levels and lead to iron deficiency anemia.
Mims embraced new opportunities at CSL Plasma and watched her career grow in a new direction that required fast-paced learnin…
The U.S. Food and Drug Administration’s new ARC program aims to enable coordination, collaboration and research support.
Working in cell transplantation, she’s motivated by “the true and genuine focus of delivering CSL’s promise to patients.”
Americas
Asia Pacific
Middle East
Europe
